Innate Pharma Revenue and Competitors

Marseille, France

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Innate Pharma's estimated annual revenue is currently $49.4M per year.(i)
  • Innate Pharma's estimated revenue per employee is $237,452
  • Innate Pharma's current valuation is $364.7M. (January 2022)

Employee Data

  • Innate Pharma has 208 Employees.(i)
  • Innate Pharma grew their employee count by -8% last year.

Innate Pharma's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
Group Human Resources VPReveal Email/Phone
3
VP, Compliance & OperationsReveal Email/Phone
4
Head Business DevelopmentReveal Email/Phone
5
VP, Program LeaderReveal Email/Phone
6
VP Compliance, IT & Portfolio ManagementReveal Email/Phone
7
VP, Global Head CommunicationsReveal Email/Phone
8
Head Translational &Technologies DepartmentReveal Email/Phone
9
EVP, Business Development and Portofolio StrategyReveal Email/Phone
10
Head transversal projectsReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$12.6M81-5%N/AN/A
#2
$19.5M126-2%N/AN/A
#3
$36.3M23422%N/AN/A
#4
$19.7M127-17%N/AN/A
#5
$14.3M920%$179.5MN/A
#6
$49.4M208-8%€201.1MN/A
#7
$44.5M287-3%N/AN/A
#8
$7.6M49N/AN/AN/A
#9
$6.4M41N/AN/AN/A
#10
$17.2M111-15%N/AN/A
Add Company

What Is Innate Pharma?

Innate Pharma S.A. is a commercial stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma?s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca, was approved by the FDA in September 2018. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia (HCL). Innate Pharma?s broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need. Pioneers in the biology of Natural Killer cell, Innate Pharma has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca. Based in Marseille, France and USA, Innate Pharma has more than 200 employees and is listed on Euronext Paris.

keywords:N/A

N/A

Total Funding

208

Number of Employees

$49.4M

Revenue (est)

-8%

Employee Growth %

$364.7M

Valuation

N/A

Accelerator

Innate Pharma News

2022-04-20 - Innate Pharma (NASDAQ:IPHA) Lifted to “Hold” at Zacks ...

According to Zacks, “Innate Pharma S.A. is a commercial stage oncology-focused biotech company. It discovers and develops therapeutic antibodies...

2022-04-20 - Innate Pharma: First Patient Dosed in Monalizumab Phase 3 ...

Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca. First patient dosed...

2022-03-30 - Innate Pharma to Hold Its Annual General Meeting of ...

Innate Pharma S.A. is a global, clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for...

2021-09-07 - Innate Pharma : Announces Conference Call and Webcast for First Half 2021 Business Update

Marseille, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Wednesday, September 15, 2021, at 2 p.m. CEST / 8 a.m. EDT, to give an update on business progre ...

2021-09-02 - Innate Pharma : Monalizumab and ANKET™ Data Will be Presented at ESMO 2021 Virtual Congress

Marseille, France, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that two oral p ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$62.4M2277%N/A
#2
$25.9M2356%N/A
#3
N/A2373%N/A
#4
$41.8M2627%N/A
#5
N/A2639%N/A